Cosentyx (secukinumab) - Novartis
Case Report: Successful treatment of pediatric patients with acute generalized pustular psoriasis with secukinumab. (PubMed, Front Med (Lausanne)) - Sep 26, 2026 - "To date, no secukinumab-related adverse effects have been observed among the three pediatric patients throughout their respective follow-up periods. Secukinumab may be an effective option for the treatment of GPP in children." 
Journal • Dermatology • Dermatopathology • Immunology • Inflammation • Pediatrics • Psoriasis • Pustular Psoriasis • IL17A
http://www.ncbi.nlm.nih.gov/pubmed/42787029
 
Bei Qin; Jia Lian; Lixin Chen; Qinfeng Li; Qiqi Liu
 
Sep 26, 2026
 
Prev Next